By Kaitlin Ugolik ( December 14, 2011, 7:22 PM EST) -- When Amylin Pharmaceuticals Inc.'s joint marketing agreement for a diabetes drug with Eli Lilly & Co. went sour this spring, the parties' lawyers devised a unique solution: They terminated the collaborative effort on a successful drug and returned the rights to Amylin through a $1.2 billion revenue sharing deal....
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
A Law360 subscription includes features such as
- Daily newsletters
- Expert analysis
- Mobile app
- Advanced search
- Judge information
- Real-time alerts
- 450K+ searchable archived articles
And more!
Experience Law360 today with a free 7-day trial.